Clinically-relevant consecutive treatment with isoproterenol and adenosine protects the failing heart against ischaemia and reperfusion
Journal of Translational Medicinevolume 12, Article number: 139 (2014)
Consecutive treatment of normal heart with a high dose of isoproterenol and adenosine (Iso/Ade treatment), confers strong protection against ischaemia/reperfusion injury. In preparation for translation of this cardioprotective strategy into clinical practice during heart surgery, we further optimised conditions for this intervention using a clinically-relevant dose of Iso and determined its cardioprotective efficacy in hearts isolated from a model of surgically-induced heart failure.
Isolated Langendorff-perfused rat hearts were treated sequentially with 5 nM Iso and 30 μM Ade followed by different durations of washout prior to 30 min global ischaemia and 2 hrs reperfusion. Reperfusion injury was assessed by measuring haemodynamic function, lactate dehydrogenase (LDH) release and infarct size. Protein kinase C (PKC) activity and glycogen content were measured in hearts after the treatment. In a separate group of hearts, Cyclosporine A (CsA), a mitochondria permeability transition pore (MPTP) inhibitor, was added with Iso/Ade. Failing hearts extracted after 16 weeks of ligation of left coronary artery in 2 months old rats were also subjected to Iso/Ade treatment followed by ischaemia/reperfusion.
Recovery of the rate pressure product (RPP) in Iso/Ade-treated hearts was significantly higher than in controls. Thus in Iso/Ade treated hearts with 5 nM Iso and no washout period, RPP recovery was 76.3 ± 6.9% of initial value vs. 28.5 ± 5.2% in controls. This was associated with a 3 fold reduction in LDH release irrespective to the duration of the washout period. Hearts with no washout of the drugs (Ade) had least infarct size, highest PKC activity and also showed reduced glycogen content. Cardioprotection with CsA was not additive to the effect of Iso/Ade treatment. Iso/Ade treatment conferred significant protection to failing hearts. Thus, RPP recovery in failing hearts subjected to the treatment was 69.0 ± 16.3% while in Control hearts 19.7 ± 4.0%. LDH release in these hearts was also 3 fold lower compared to Control.
Consecutive Iso/Ade treatment of normal heart can be effective at clinically-relevant doses and this effect appears to be mediated by glycogen depletion and inhibition of MPTP. This intervention protects clinically relevant failing heart model making it a promising candidate for clinical use.
Reperfusion following a prolonged period of ischaemia induces myocardial dysfunction and necrotic damage . Ischaemia and reperfusion–elicited tissue injury contributes to morbidity and mortality in a wide range of pathologies and is a major challenge during organ transplantation and cardiothoracic, vascular and general surgery .
We have previously described a cardioprotective protocol termed temperature preconditioning (TP)  where a few brief episodes of hypothermic perfusion (at 26°C) interspersed with normothermic perfusion (at 37°C) significantly improved heart resistance to the subsequent index ischaemia. The cardioprotective effect of TP, which exceeds the effect of ischaemic preconditioning, is associated with activation of protein kinases A (PKA) and C (PKC) and can be abolished by inhibitors of PKA and PKC (H-89 and chelerythrine, respectively) [3, 4]. Furthermore, a combination of TP with the PKA inhibitor H-89 (which has no direct effect on PKC) reduced activation of PKC indicating that in the mechanism of TP, PKC activation occurs downstream to activation of PKA . Importantly, TP mediated by the consecutive activation of PKA and PKC protects hearts during global normothermic ischaemia and during hypothermic ischaemia and cardioplegia . When the consecutive activation of PKA and PKC was mimicked pharmacologically using the PKA activator isoproterenol (Iso) and the PKC activator adenosine (Ade), it resulted in a highly potent cardioprotective effect . This was achieved using a concentration of Iso (200 nM) significantly higher than the concentration of isoproterenol in blood plasma used clinically (0.02-0.2 μg/kg/min; equivalent to about 1.3-13 nM) . In contrast, the concentration of adenosine used in our experiments (30 μM) is considerably lower than that used for blood cardioplegia during cardiac surgery (1–2 mM) [7, 8]. Therefore it is important to test both drugs at concentrations that are clinically relevant. Furthermore, in our earlier work investigating this intervention, we had not explored what duration of the washout period prior to ischaemia produced the maximal cardioprotective effect by triggering signalling mechanisms.
It is now recognized that opening of the mitochondria permeability transition pore (MPTP) plays a key role in mediating the irreversible damage of the myocardium during reperfusion  and that a range of interventions that inhibit pore opening, either directly or indirectly, are cardioprotective [10–12]. This was confirmed for the cardioprotective effect of consecutive Iso/Ade treatment with Iso used at relatively high concentration  but has not been investigated at a clinically relevant concentration. This can be achieved by establishing whether the cardioprotective effects of Iso/Ade treatment are additive to those of cyclosporine A (CsA) which is one of the most effective inhibitors of MPTP  widely used in experiments on isolated hearts.
The presence of co-morbid illness can render the myocardium resistant to cardioprotection against infarction by physical or pharmacological stimuli . Thus an important and necessary step towards translation of this cardioprotective strategy into clinical practice is to study the efficacy of consecutive Iso/Ade treatment in diseased hearts.
Here we study whether our treatment is effective at low, clinically relevant concentrations of Iso and optimize the protocol of the consecutive Iso/Ade treatment. We confirm the underlying mechanism to be inhibition of MPTP opening and that the treatment is effective in a surgically-induced model of heart failure.
Unless otherwise stated, all biochemicals were purchased from Sigma and general chemicals from Fischer Scientific or VWR-Jencons.
Heart perfusion and analysis of haemodynamic function
All procedures conform to the Directive 2010/63/EU of the European Parliament and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996). Ethical approval was granted by the University of Bristol, UK. Two months old male Wistar rats (250–260 g) were killed by stunning and cervical dislocation. Hearts (~0.75 g) were rapidly removed into ice-cold Krebs-Henseleit buffer (KH) containing (mm): NaCl 118, NaHCO3 25, KCl 4.8, KH2PO4 1.2, MgSO4 1.2, glucose 11 and CaCl2 1.2, gassed with 95% O2-5% CO2 at 37 °C (pH 7.4) and perfused in Langendorff mode. The aorta was rapidly cannulated and the heart perfused at a rate of 8 ml · min−1 · g−1 heart weight with in-line filter using KH. Monitoring of left ventricular pressure was performed with a water-filled balloon inserted into the left ventricle, set to give an initial left ventricular end diastolic pressure (LVEDP) of 2.5–5 mmHg. All hearts were allowed an equilibration period of at least 25 min before any additional treatments was given. Data acquisition and analysis used a PowerLab System (ADInstruments, Australia). Left ventricular developed pressure (LVDP) was calculated as the difference between left ventricular systolic pressure (LVSP) and LVEDP, and work index (RPP) as the product of LVDP and heart rate (HR). Time derivatives of pressure were measured during contraction (+dP/dt) and relaxation (−dP/dt). The haemodynamic parameters were computed using the software Chart 5 (ADInstruments, Australia). Preischaemic values of the parameters of haemodynamic function were measured at the end of the equilibration period prior to any preischaemic intervention. Since the hearts in our experiments contracted spontaneously, haemodynamic function is reflected in both LVDP and HR. For this reason, RPP was considered as the main parameter characterising haemodynamic function. If RPP was less than 15,000 mmHg·beat/min at the end of the preischaemic equilibration period, the heart was excluded from the experiment.
Model of Surgically-Induced Heart Failure
Heart failure was surgically induced by ligation of the left coronary artery as described previously  and modified in our laboratory. In brief, 2 month old rats were anesthetized with ketamine (75 mg/kg, i.p.) and medetomidine (0.5 mg/kg, i.p.). Analgesia was induced by buprenorphine (0.05 mg/kg, s.c.). The rats were intubated and ventilated with a respirator for small animals (Harvard Apparatus). Body temperature was maintained at 37°C during the surgical procedure. An incision was made in the left side of the chest to expose the fourth intercostal space. A 7–0 surgical suture was placed under the left coronary artery and tied to complete occlusion of the artery. In sham-operated animals (SO), the coronary artery was not ligated. The wound was closed with a 4–0 surgical suture. Atipamezole (2.5 mg/kg, i.p.) was injected in order to facilitate recovery after the anaesthesia. After the surgery, rats were placed into a recovery chamber (Vet Tech Solutions Ltd) ventilated with oxygen. In coronary artery ligated (CAL) animals, approximately 92% survived and were able to meet the inclusion criteria for the experiments on isolated heart. All sham operated animals survived to 16 weeks after surgery. Animals were monitored and cared for daily. Sixteen weeks after surgery, the animals were used for experiments on isolated heart as shown in the Methods.
After a 25 min period of equilibration followed by preischaemic interventions, global normothermic ischaemia (37°C) was induced for 30 min and then normothermic perfusion was reinstated for 2 hr. Three series of experiments were performed as detailed below and summarised in Figures 1 and 2. In Series 1 and 2, experiments were carried out on healthy male Wistar rats (250–275 g) whilst in Series 3 rats with surgically-induced heart failure or sham-operated rats were employed.In Series 1 (Figure 1A), hearts were divided into a Control group and 4 treatment groups (8–10 hearts/group) according to the preischaemic protocol. Hearts of the Control group were not subjected to any intervention prior to ischaemia. Hearts of the three treatment groups, after the equilibration period, were subjected to the consecutive perfusion with Iso and Ade (3 min with 5 nM Iso and 5 min with 30 μM Ade) followed by a washout period of different duration: 10 min (Iso/Ade-10); 5 min (Iso/Ade-5) and zero min (Iso/Ade-0). Hearts of the fourth treatment group ((Iso/Ade Mix)) were perfused with Ade for 1.5 min and then 3 min with the mixture of Iso and Ade followed by another 1.5 min period of perfusion with Ade (Figure 1A). Analysis of haemodynamic function recovery, lactate dehydrogenase (LDH) release during reperfusion and infarct size, in this and the other series of experiments, was performed in all hearts subjected to ischaemia. Additional hearts (n = 9-10/group) of Control, Iso/Ade-10 and Iso/Ade-0 groups were freeze-clamped following 43 min preischaemia, ground under liquid nitrogen and stored at −80°C for later analysis of PKC activity. Another set of Control, Iso/Ade-0 and Iso/Ade Mix hearts (n = 7-8 in each group) were freeze-clamped at the end of the preishaemic protocol and used for the measurement of glycogen content.In Series 2 experiments, four groups (6–9 hearts/group) were employed (Figure 1B). Two of the groups were Control and Iso/Ade with no washout period. In this series of experiments and in the Series 3 experiments, Iso was used at 10 nM. In preliminary experiments (data not shown), we found that this concentration of Iso might give even higher cardioprotective effect than 5 nM, which is important in terms of optimisation of the intervention, yet was still in the range of normal pharmacological dose. Another two groups of hearts were perfused with 0.2 μM CsA for 8 min prior to ischaemia with or without the Iso/Ade treatment (Iso/Ade + CsA and CsA groups respectively).Series 3 experiments were carried out on CAL and SO rats. Hearts were divided into four groups (5–6 hearts/group): Control and Iso/Ade groups of CAL and SO rats. The experimental protocol of Control and Iso/Ade groups (Figure 2) in this series of experiments was similar to those in Series 2 (Figure 1B). Infarct size was not measured in these experiments because the CAL hearts had already developed an infarct as a result of the left descending coronary artery ligation.
Five additional CAL and 6 SO rats were used to confirm the development of heart failure. Body weight and tibia length were measured before the surgery and 16 weeks after the operation. After 16 weeks post-operation, the rats were killed by stunning and cervical dislocation, the hearts and lungs excised and the wet weight of the hearts, left ventricles and lungs were measured.
PKC activity was determined in freeze-clamped heart powders using a kit supplied by Promega according to the manufacturer’s instructions. The assay relies on a change in charge of the fluorescent PepTag® C1 peptide from +1 to −1 following phosphorylation. Bands were visualized under UV light and the ratio of fluorescence intensity of phosphorylated to non-phosphorylated peptide was quantified using AlphaInotech ChemiImager 4400 with AlphaEase v5.5 software.
Glycogen content in myocardium
Glycogen content was assessed by measuring the glucose released from glycogen breakdown by amyloglucosidase based on the method described by Passonneau  and expressed as μmol glucose per gram tissue. A sample (70 mg) of the frozen tissue was suspended in 1 ml of 0.3 M perchloric acid (4°C), homogenized with a Polytron and 50 μl of the suspension were incubated with 0.5 ml of 50 mM Na Acetate Buffer (pH 5.5) containing 0.02% BSA and 50 μg/ml amyloglucosidase (Sigma) at room temperature for 2 hr. The samples were then centrifuged at 10000 g for 10 min and glucose content was assessed using a Glucose (HK) Assay Kit (Sigma) according to the manufacturer’s instruction. Briefly, 0.4 ml of the supernatant was mixed with 1 ml of the glucose assay reagent. Glucose content was measured spectrophotometrically (340 nm) after incubation at room temperature for 15 min.
The quantity of glucose released from glycogen breakdown was determined by subtracting glucose in samples incubated without amyloglucosidase from those incubated with the enzyme.
LDH activity was determined in the effluent perfusate collected from the hearts of all groups prior to ischemia and during each 5 min over the first 30 min of reperfusion as described earlier  and modified at our lab: 80 μl of the sample was added to 910 μl of the buffer (pH 7.4) containing 100 mM triethanolamine and 100 μM reduced β-nicotinamide adenine dinucleotide (NADH). After addition of 10 μl of 0.1 M sodium pyruvate to the reaction mixture, the change of absorbance at 340 nm (A340) was recorded using a spectrophotometer over 10 min at 37°C. LDH activity was calculated according to the rate of A340 decrease.
Infarct size was determined as described previously . Hearts were stained with 1% of triphenyltetrazolium chloride after 2 h of reperfusion, frozen at -20°C and sliced into 6 slices. Necrotic and intact areas of each side for each of heart slices were determined using AlphaEase v5.5 software and the total necrotic and intact area of ventricular myocardium of each heart was calculated. Since the entire heart was at risk from global ischemia, the infarct size was expressed dividing the sum of necrotic areas by the sum of total slice areas of the 6 slices to obtain the percentage of necrosis.
Data are presented as mean ± SEM. Statistical significances of the differences between groups were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test or two-tailed unpaired Student’s t-test (morphometric measurements of CAL and SO rats in the Series 3 experiments) using the software GraphPad Prism, Version 4.03. Differences were considered significant where P < 0.05.
Optimization of the protocol of Iso/Ade treatment with a clinically relevant dose of Isoproterenol
In the Iso/Ade group, RPP during heart perfusion with 5 nM Iso reached a maximum of 259.4 ± 12.4% of the pre-treatment value, mostly due to an increase in LVDP. RPP measured at the end of perfusion with 30 μM Ade fell to 42.3 ± 7.0% of the pre-treatment value, due to a significant reduction of both HR and LVDP. In Table 1, we show that during reperfusion, recovery of RPP in the Control group was 28%. However, perfusion with low Iso concentration (5 nM) followed by 30 μM Ade immediately prior to rendering the heart ischaemia (Iso/Ade-0 group), improved recovery in RPP to 76%. Similar recovery was achieved when the duration of perfusion prior to commencing ischaemia was extended to 5 or 10 min (Iso/Ade-5 and Iso/Ade-10 groups).The improved RPP recovery during reperfusion was accompanied by considerably reduced LVEDP and reflected improved recovery of LVDP with no significant change in HR. The time derivative during contraction was significantly higher in all three Iso/Ade groups than in Control group, whereas recovery of -dP/dt was significantly improved only in hearts of the Iso/Ade-0 group. The parameters of haemodynamic function recovery did not differ significantly between the three Iso/Ade groups but were the highest in Iso/Ade-0 group. Protection against necrotic damage showed a similar pattern to the recovery of haemodynamic function. Thus, LDH release during the first 30 min of reperfusion (Figure 3A) and infarct size at the end of reperfusion (Figure 3B) were significantly lower in Iso/Ade groups compared to Control. However infarct size in the group Iso/Ade-0 was notably lower compared to both Control and Iso/Ade-5 groups.PKC activity in Iso/Ade-0 group, measured at the end of the pre-ischaemic protocol, was 1.5 fold higher compared to both Control and Iso/Ade-10 groups (Figure 4).Glycogen content was halved in hearts treated consecutively with Iso and Ade, but simultaneous perfusion of hearts with these drugs had no significant effect on this parameter (Figure 5).
Effect of the combined treatment with Iso, Ade and cyclosporine A on ischaemia/reperfusion injury
In the Iso/Ade group of the second series of experiments, RPP during heart perfusion with 10 nM of Iso reached a maximum of 346.1 ± 26.9% of the pre-treatment value, significantly exceeding RPP increase in Series 1 hearts treated with 5 nM Iso (P < 0.05). This elevation of RPP was mostly due to increase in LVDP. RPP measured at the end of perfusion with 30 μM Ade fell to 36.8 ± 7.6% of the pre-treatment value due to a significant reduction of both HR and LVDP. The MPTP inhibitor CsA significantly increased RPP recovery compared to Control (Table 2) and was as effective as the consecutive Iso/Ade treatment in terms of reduction of infarct size (Figure 6B). LDH activity in the effluent perfusate during reperfusion was also significantly reduced in these hearts (Figure 6A). However perfusion of hearts with CsA together with the consecutive Iso/Ade treatment (Iso/Ade + CsA group), at clinically relevant concentration of these drugs, did not bring about any additive protective effect; infarct size and LDH release were similar to those of Iso/Ade group.
Consecutive Iso/Ade treatment protects hearts with surgically-induced heart failure
At the time of the ligation of left coronary artery, no significant difference in body weight or tibia length was detected between sham-operated (SO) and Coronary Artery Ligation (CAL) animals. After 16 weeks post-surgery, there was no difference in body weight between the two groups. However, significant increases in heart and lung weights, heart and lung to body weight ratios, as well as tibia length to body weight ratio in the CAL animals were observed (Table 3) indicating both cardiac hypertrophy and cardiac insufficiency.
During heart perfusion with 10 nM of Iso, RPP reached a maximum of 401.3 ± 30.8% of the pre-treatment value in SO group and 343.3 ± 52.4% in CAL group, mostly due to increase in LVDP. This parameter in the SO group, but not in the CAL group, was significantly higher than in Series 1 where the hearts were treated with 5 nM Iso (P < 0.01). RPP measured at the end of perfusion with 30 μM Ade fell to 43.5 ± 8.0% of the pre-treatment value in SO hearts and to 56.6 ± 9.3% in CAL hearts, due to a significant reduction of HR and return of LVDP to the pre-treatment value. There was no significant difference in changes of RPP in response to the perfusion with Ade between SO and CAL groups. Haemodynamic function recovery of both SO and CAL groups of hearts following ex-vivo ischaemia/reperfusion was very poor and did not significantly differ from each other (Table 4). Thus, LVDP and RPP reached only 20–25% of the initial preischaemic values. Iso/Ade treatment significantly improved haemodynamic function recovery of both SO and CAL hearts with RPP reaching 70% of the preischaemic value. LDH activity during reperfusion was highest in Control CAL hearts and was significantly higher not only than Iso/Ade treated hearts of SO and CAL groups but also than Control SO hearts (Figure 7). Thus, necrotic damage was greatest in the untreated failing hearts but Iso/Ade treatment was able to protect the failing hearts at least as effectively as the sham-operated ones.
Optimisation of the Iso/Ade treatment and its translational significance
Our results show that Iso at its low dose (5–10 nM), followed by the perfusion with 30 μM Ade, can successfully protect hearts against ischaemia/reperfusion injury. In fact, when Iso was perfused at 10 nM, the protective effect was similar to the higher concentration of Iso (200 nM) used in our previous experiments . Since both Iso and Ade are used in clinical settings and can protect hearts at clinically relevant doses, the consecutive Iso/Ade treatment has strong potential for translation into clinical practice. Furthermore, the use of these drugs at low doses will minimise other drug interactions. This work also demonstrates that there is a window of at least 10 min within which the index ischaemia can be started and strong cardioprotection still be observed. However, it is clear that, the shorter the period between the end of the treatment and the start of ischaemia the higher the cardioprotective efficacy of the treatment will be. Thus in our experiments, infarct size in hearts with no washout period (Iso/Ade-0 group) was significantly smaller than in both Control and Iso/Ade-5 hearts. Furthermore, only in Iso/Ade-0 hearts was -dP/dt recovery significantly higher than in controls. This might be explained by the index ischaemia in these hearts commencing while PKC remained activated, potentially leading to more effective survival signalling.
Having established that clinically-relevant doses of isoproteronol and adenosine are cardioprotective and was optimal when applied immediately prior to ischaemia, the next step was to identify the target of this powerful cardioprotective intervention. Our earlier work suggested that reduced ROS production and consequent inhibition of MPTP opening were likely targets . If this is the case, protection should not be further enhanced by direct inhibition of the MPTP by Cyclosporin A and we confirmed this to be the case.
Role of MPTP and Cardiac Glycogen in cardioprotection by Iso/Ade treatment
We  and others [19–21] have shown that MPTP opening is a key factor of irreversible damage during reperfusion and that its prevention underlies cardioprotection by a variety of preconditioning  and post-conditioning protocols . Thus, it was hypothesized that the protection associated with ischaemic preconditioning could be attributed to a decreased probability of MPTP opening [9, 22]. Ovize et al. proposed MPTP inhibition as the effector of ischaemic postconditioning . It has been shown that the protective effect of remote ischaemic preconditioning  and a variety of pharmacologically-induced cardioprotective interventions  also rely on the MPTP inhibition. In our recent study with Iso/Ade treatment, where Iso was used at relatively high concentration (200 nM), the treatment resulted in a dramatic reduction of calcium-induced mitochondria swelling implicating MPTP inhibition as an end effector of the cardioprotective mechanism .
In the present work, we used the MPTP inhibitor CsA in order to confirm a role for MPTP inhibition in the cardioprotection afforded by Iso/Ade treatment. We found that CsA improved RPP recovery and significantly reduced necrotic damage to myocardium during reperfusion. These results are consistent with earlier data shown by us [23, 24] and others [25–27] confirming a cardioprotective effect of CsA. However, no additive cardioprotective effect was seen when consecutive treatment with 10 nM isoproterenol and 30 μM adenosine was combined with CsA treatment. These data suggest that cardioprotection by the Iso/Ade treatment is mediated through inhibition of the MPTP.
It has been reported that protection via ischaemic preconditioning is associated with glycogen depletion leading to less anaerobic glycolysis during the subsequent prolonged ischaemia, and hence reduced accumulation of lactate and H+. This causes a smaller decrease in intracellular pH during ischaemia and thus less compensatory increases in intracellular Na+ and Ca2+. The decreased Ca2+ loading will reduce the likelihood that the MPTP opens which might partially explain the observed cardioprotection . Glycogen breakdown has also been linked to attenuation of the loss of hexokinase 2 (HK-2) binding to mitochondria that occurs during ischaemia . The binding of HK-2 plays an anti-apoptotic role and inhibits MPTP opening [31, 32] and there is an inverse correlation between the extent of HK-2 binding at the end of ischaemia and infarct size . Increase HK-2 binding at the end of ischaemia can be mediated, at least in part, by decreasing tissue glycogen content prior to ischaemia. This leads to a reduction in tissue glucose-6-phosphate levels and acidification during ischaemia, which mediate HK-2 dissociation from mitochondria . The data of Figure 5 confirm that the consecutive Iso/Ade treatment also depleted glycogen content considerably consistent with this mechanism, whereas the reduction in glycogen content following simultaneous application of the drugs was not significant and was accompanied by considerably less cardioprotection. However, reduced glycogen content cannot entirely account for the cardioprotection since we have shown previously that a similar decrease in glycogen could be induced by high dose of isoproterenol alone, yet this treatment was less cardioprotective than the consecutive treatment with isoproterenol and adenosine . Thus adenosine may contribute to cardioprotection through glycogen independent mechanisms that improve haemodynamic function recovery during reperfusion and inhibit MPTP opening .
Consecutive Iso/Ade treatment protects hearts with surgically-induced heart failure
Since the majority of patients undergoing cardiac surgery suffer from co-morbid illnesses, for clinical use of consecutive Iso/Ade treatment it is necessary to confirm its efficacy in an experimental model of the diseased heart [33, 34]. In general, the presence of co-morbid illness renders the myocardium resistant to cardioprotection against infarction by physical or pharmacological stimuli . It has been found that compensated left ventricular hypertrophy does not compromise the efficacy of cardioprotective interventions such as ischaemic preconditioning but heart failure abolishes any beneficial effect [33, 35, 36]. Heart failure is a complex clinical syndrome, the etiology of which generally stems from pre-existing ischaemic heart/coronary artery disease, or it is of non-ischaemic and/or idiopathic origin [37, 38]. It is characterized by the progressive inability of the heart to fill with, and eject adequate amounts of blood to meet the needs of the body .
Ligation of the left descending coronary artery in our experiments rendered a significant increase in heart and lung weight to body weight and tibia length ratios (Table 3) in 16 weeks after the surgery indicating both cardiac hypertrophy and cardiac insufficiency.Consistent with the dose-dependent effect, preischaemic perfusion of SO hearts with 10 nM Iso resulted in a significantly higher increase of RPP than in hearts of Series 1 treated with 5 nM Iso. In the CAL group, RPP was also increased considerably during perfusion with 10 nM Iso but this was not significantly higher than in hearts treated with 5nM Iso. Thus, although the myocardium of rats with surgically-induced heart failure model showed somewhat reduced β-adrenergic reactivity, they still responded well to the β-adrenergic stimulation. Control CAL hearts suffered more severe necrotic damage during reperfusion than their sham-operated counterparts as reflected in the released LDH activity during reperfusion which was twice as high in these hearts as compared to the non-treated SO hearts (Figure 7). Nevertheless, the haemodynamic function recovery in Iso/Ade treated CAL hearts was similar to SO hearts whilst LDH release was suppressed more strongly than in the sham-operated hearts. This implies that heart failure in our experiments did not compromise the cardioprotective effect of consecutive Iso/Ade treatment and that the survival signal transduction pathways activated by this treatment were still responsive in spite of the developed heart failure.
The results of our study may represent a significant step towards translation of the consecutive Iso/Ade treatment to cardiac surgery involving ischaemic cardioplegic arrest and cardiopulmonary bypass.
The novel findings of our study are as follows:
Strong cardioprotective effect of PKA/PKC activation can be achieved by heart perfusion with Iso at the clinically relevant concentration of 5–10 nM followed by perfusion with Ade.
The cardioprotective efficacy of PKA/PKC activation remains for at least 10 min after the intervention. From a practical point of view, this means that this protective intervention will still be effective even if it is performed some time before the ischaemic incident (i.e. cardiac surgery with cardioplegic arrest).
In contrast to a number of studies showing loss or attenuation of cardioprotection in diseased or ageing hearts, consecutive Iso/Ado treatment can protect the failing heart effectively. This efficacy of the treatment in a relevant comorbidity model increases the likelihood of successful translation into clinical practice.
Our data suggest a key role of MPTP inhibition in the cardioprotective effect of this treatment. Glycogen depletion of the myocardium induced by the treatment prior to ischaemia is implicated in the mechanism underlying MPTP inhibition and cardioprotection.
Coronary artery ligated
Left ventricular developed pressure
Left ventricular end-diastolic pressure
Left ventricular systolic pressure
Mitochondria permeability transition pore
Protein kinase A
Protein kinase C
Time derivatives of pressure during contraction
Time derivative of pressure during relaxation.
Depre C, Taegtmeyer H: Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc Res. 2000, 45: 538-548. 10.1016/S0008-6363(99)00266-7.
Eltzschig HK, Eckle T: Ischemia and reperfusion–from mechanism to translation. Nat Med. 2011, 17: 1391-1401. 10.1038/nm.2507.
Khaliulin I, Clarke SJ, Lin H, Parker JE, Suleiman MS, Halestrap AP: Temperature preconditioning of isolated rat hearts - a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore. J Physiol. 2007, 581: 1147-1161. 10.1113/jphysiol.2007.130369.
Khaliulin I, Parker JE, Halestrap AP: Consecutive pharmacological activation of PKA and PKC mimics the potent cardioprotection of temperature preconditioning. Cardiovasc Res. 2010, 88: 324-333. 10.1093/cvr/cvq190.
Khaliulin I, Halestrap AP, Suleiman MS: Temperature preconditioning is optimal at 26°C and confers additional protection to hypothermic cardioplegic ischemic arrest. Exp Biol Med. 2011, 236: 736-745. 10.1258/ebm.2011.010357.
Gilmore K, Nanyanzi C: Pharmacology of vasopressors and inotropes. Update Aneasthesia. 1999, 10: 1-2.
Mentzer RM, Birjiniuk V, Khuri S, Lowe JE, Rahko PS, Weisel RD, Wellons HA, Barker ML, Lasley RD: Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999, 229: 643-649. 10.1097/00000658-199905000-00006. discussion 649–650
Liu R, Xing J, Miao N, Li W, Liu W, Lai Y-Q, Luo Y, Ji B: The myocardial protective effect of adenosine as an adjunct to intermittent blood cardioplegia during open heart surgery. Eur J Cardiothorac Surg. 2009, 36: 1018-1023. 10.1016/j.ejcts.2009.06.033.
Halestrap AP, Clarke SJ, Khaliulin I: The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta. 2007, 1767: 1007-1031. 10.1016/j.bbabio.2007.05.008.
Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M: Postconditioning inhibits mitochondrial permeability transition. Circulation. 2005, 111: 194-197. 10.1161/01.CIR.0000151290.04952.3B.
Wang L, Oka N, Tropak M, Callahan J, Lee J, Wilson G, Redington A, Caldarone CA: Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg. 2008, 136: 335-342. 10.1016/j.jtcvs.2007.12.055.
Heusch G, Boengler K, Schulz R: Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol. 2010, 105: 151-154. 10.1007/s00395-009-0080-9.
Liu L, Zhu J, Brink PR, Glass PSA, Rebecchi MJ: Age-associated differences in the inhibition of mitochondrial permeability transition pore opening by cyclosporine A. Acta Anaesthesiol Scand. 2011, 55: 622-630. 10.1111/j.1399-6576.2011.02421.x.
Ludman AJ, Yellon DM, Hausenloy DJ: Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech. 2010, 3: 35-38. 10.1242/dmm.003855.
Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E: Myocardial infarct size and ventricular function in rats. Circ Res. 1979, 44: 503-512. 10.1161/01.RES.44.4.503.
Passonneau JV, Lauderdale VR: A comparison of three methods of glycogen measurement in tissues. Anal Biochem. 1974, 60: 405-412. 10.1016/0003-2697(74)90248-6.
Bergmeyer H-U, Bernt E: Lactate dehydrogenase. Methods of Enzymatic Analysis. Edited by: Bergmeyer H-U. 1963, London: Academic, 574-579.
Pasdois P, Beauvoit B, Costa ADT, Vinassa B, Tariosse L, Bonoron-Adèle S, Garlid KD, Santos PD: Sarcoplasmic ATP-sensitive potassium channel blocker HMR1098 protects the ischemic heart: Implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J Mol Cell Cardiol. 2007, 42: 631-642. 10.1016/j.yjmcc.2006.12.014.
Di Lisa F, Bernardi P: Mitochondria and ischemia–reperfusion injury of the heart: Fixing a hole. Cardiovasc Res. 2006, 70: 191-199. 10.1016/j.cardiores.2006.01.016.
Baines CP: The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol. 2009, 104: 181-188. 10.1007/s00395-009-0004-8.
Weiss JN, Korge P, Honda HM, Ping P: Role of the mitochondrial permeability transition in myocardial disease. Circ Res. 2003, 93: 292-301. 10.1161/01.RES.0000087542.26971.D4.
Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP: Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol. 2003, 549: 513-524. 10.1113/jphysiol.2003.034231.
Griffiths EJ, Halestrap AP: Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol. 1993, 25: 1461-1469. 10.1006/jmcc.1993.1162.
Clarke SJ, McStay GP, Halestrap AP: Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem. 2002, 277: 34793-34799. 10.1074/jbc.M202191200.
Onishi A, Miyamae M, Kaneda K, Kotani J, Figueredo VM: Direct evidence for inhibition of mitochondrial permeability transition pore opening by sevoflurane preconditioning in cardiomyocytes: Comparison with cyclosporine A. Eur J Pharmacol. 2012, 675: 40-46. 10.1016/j.ejphar.2011.11.040.
Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN: Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol. 2007, 42: 150-158. 10.1016/j.yjmcc.2006.09.013.
Weinbrenner C, Liu GS, Downey JM, Cohen MV: Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. Cardiovasc Res. 1998, 38: 676-684. 10.1016/S0008-6363(98)00064-9.
Cross HR, Opie LH, Radda GK, Clarke K: Is a high glycogen content beneficial or detrimental to the ischemic rat heart? : A controversy resolved. Circ Res. 1996, 78: 482-491. 10.1161/01.RES.78.3.482.
Halestrap AP, Pasdois P: The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta. 2009, 1787: 1402-1415. 10.1016/j.bbabio.2008.12.017.
Pasdois P, Parker JE, Halestrap AP: Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. J Am Heart Assoc. 2013, 2: e005645-
Pastorino J, Hoek J: Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr. 2008, 40: 171-182. 10.1007/s10863-008-9148-8.
Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, Sollott SJ, Forte M, Bernardi P, Rasola A: Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One. 2008, 3: e1852-10.1371/journal.pone.0001852.
Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007, 59: 418-458. 10.1124/pr.107.06002.
Balakumar P, Singh H, Singh M, Anand-Srivastava MB: The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res. 2009, 60: 18-23. 10.1016/j.phrs.2009.03.002.
Gaasch WH, Zile MR, Hoshino PK, Weinberg EO, Rhodes DR, Apstein CS: Tolerance of the hypertrophic heart to ischemia: Studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation. 1990, 81: 1644-1653. 10.1161/01.CIR.81.5.1644.
Andersen A, Povlsen JA, Bøtker HE, Nielsen-Kudsk JE: Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-conditioning. Eur J Heart Fail. 2013, 15: 1208-1214. 10.1093/eurjhf/hft105.
Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC: Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010, 90: 207-258. 10.1152/physrev.00015.2009.
Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005, 85: 1093-1129. 10.1152/physrev.00006.2004.
Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD: Targeting fatty acid and carbohydrate oxidation — A novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 1813, 2011: 1333-1350.
The authors thank Clive Orchard (Bristol) for his contribution to the establishment of the heart failure model. This work was supported by a grant from the British Heart Foundation (PG/11/79/29125). Simon M Bryant was supported by a British Heart Foundation project grant (PG/10/91/28644).
The authors declare that they have no competing interests.
IK participated in design of the study, carried out data acquisition, data analysis and drafted the manuscript. APH participated in design of the study and helped to draft the manuscript. SMB provided the surgically-induced model of heart failure. DJD took part in the data acquisition and data analysis. AFJ participated in design and coordination of the study and helped to draft the manuscript. MSS conceived the study, participated in its design and coordination and helped to draft the manuscript. All authors have read and approved the final manuscript.